Helicobacter pylori eradication and associated factors: dual therapy versus standard triple therapy in Lima, Peru
DOI:
https://doi.org/10.47892/rgp.2025.453.1920Keywords:
Helicobacter pylori, Proton Pump Inhibitors, Stomach NeoplasmsAbstract
Objective: Helicobacter pylori (H. pylori) infection is the most important risk factor for gastric cancer development. Dual therapy can achieve higher eradication rates than standard triple therapy, and the factors associated with lower eradication rates have not been fully studied. The objective of our study was to evaluate the H. pylori eradication rate and its associated factors using dual therapy versus standard triple therapy. Materials and methods: This retrospective cohort study included 1,506 patients with H. pylori infection who received dual therapy or standard triple therapy. Eradication was confirmed with urea breath test. Chi-square (χ) test was used to analyze categorical variables, and relative risk (RR) was used to assess associations between eradication rates and clinical variables. Results: Eradication was higher with dual therapy, with 84.58% (384/454) versus 73.86% (777/1052) with standard triple therapy (p<0.001). The overall eradication rate with esomeprazole was 82.13% (648/789), followed by lansoprazole at 73.70% (213/289) and pantoprazole at 70.09% (300/428) (p<0.001). No significant differences were found regarding comorbidities such as diabetes, hypertension, or dyslipidemia. Conclusions: The H. pylori eradication rate with dual therapy was superior to standard triple therapy. The proton pump inhibitor with the highest eradication rate was esomeprazole. There were no significant differences in eradication according to sex, age, or comorbidities.
Downloads
Metrics
References
El-Assaad F, Gong L, Gia A. Helicobacter pylori, enfermedad ulcerosa péptica y cáncer gástrico. In: Eslick GD, editor. Enfermedades gastrointestinales e infecciones asociadas. España: Elsevier; 2020, p. 17-29.
Hooi J, Lai W, Ng W, Suen M, Underwood F, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420- 429. doi: 10.1053/j.gastro.2017.04.022.
Pareja A, Navarrete J, Parodi F. Seroprevalencia de infección por Helicobacter pylori en población adulta de Lima, Perú 2017. Horiz Méd. 2017;17(2):55-8. doi: 10.24265/horizmed.2017. v17n2.8.
Aziz R, Khalifa M, Sharaf R. Contaminated water as a source of Helicobacter pylori infection: A review. J Adv Res. 2015;6(4):539-47. doi: 10.1016/j.jare.2013.07.007.
Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases. 2021;9(4):66. doi: 10.3390/ diseases9040066.
Seoane A, Bessa X, Balleste B, O’Callaghan E, Panadès A, Alameda F, et al. Helicobacter pylori and gastric cancer: relationship with histological subtype and tumor location. Gastroenterol Hepatol. 2005;28(2):60-4. doi: 10.1157/13070701.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi: 10.3322/ caac.21834.
Cardos A, Maghiar A, Zaha D, Pop O, Fritea L, Miere Groza F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics (Basel) 2022;12(2):508. doi: 10.3390/diagnostics12020508.
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022;71(9):1724-62. doi: 10.1136/gutjnl-2022-327745.
Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, et al. A 14-day esomeprazole-and amoxicillin-containing highdose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718-24. doi: 10.1093/jac/dkz046.
Yun JW, Wang C, Yu Y, Xu HM, Gou LZ, Li XL, et al. High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomized controlled trial. Br J Clin Pharmacol. 2023;89(1):232-41. doi: 10.1111/bcp.15488.
Darraj M. Eradication Rate and Factors Influencing Helicobacter pylori Infection Clearance Using Standard Triple Therapy at a Single Centre in Jazan Region, Saudi Arabia: A Retrospective Study. Int J Gen Med. 2024;17:2627-34. doi: 10.2147/ijgm.s456865.
Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801-7. doi: 10.3904/ kjim.2015.30.6.801.
McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: Esomeprazole or rabeprazole vs. firstgeneration pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-25. doi: 10.1111/j.1365-2036.2012.05211.x.
Ahmed A, Balata GF, Elsadek HM, El-Din MN, Amin A. HighDose Dual Therapy versus Triple Therapy for Treatment of H. Pylori Infection: A Parallel Randomized Study. Int J Res Pharm Sci. 2020; 11:2158-64. doi: 10.26452/ijrps.v11iSPL4.4437.
Reyes D, Remes-Troche J, Laudanno O, Otero W, Piscoya A, Ramírez J, et al. Quadruple and dual therapies are superior to standard clarithromycin-based triple therapy for Helicobacter pylori first-line eradication therapy used in the Latin American registry on the management of Helicobacter pylori infection (Hp-LATAMReg). Gastroenterology. 2024;166(5):438-39. doi: 10.46613/congastro2023-144.
Villavicencio R, Sánchez G, Chávez C, Loza C, Espinoza J. Resistencia antibiótica de Helicobacter pylori en la población peruana: una revisión sistemática y metaanálisis sobre su prevalencia en la población general. Rev Gastroenterol Peru. 2022;42(3):151-62. doi: 10.47892/rgp.2022.423.1403.
von Muhlenbrock C, Cordova A, Nuñez P, Pacheco N, Herrera K, Quera R. Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile. Helicobacter. 2024;29(1):e13052. doi: 10.1111/hel.13052.
Fernández-Salazar L, Campillo A, Rodrigo L, Pérez-Aisa A, González-Santiago JM, Segarra X, et al. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg). J Clin Med. 2022;11(12):3544. doi: 10.3390/ jcm11123544.
Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol. 2020;31(3): 234–238. doi: 10.5152/tjg.2020.18974.
Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol. 2019;30(5):420-435. doi: 10.5152/tjg.2019.18693.
Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, et al. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2020;13:1-12. doi: 10.1177/1756284820937115.
Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials. J Clin Gastroenterol. 2021;55(10):856-864. doi: 10.1097/ MCG.0000000000001448.
Guan JL, Xu TT, Lin Y, Mo YS, He BY, Han YY, et al. High-dose dual therapy for Helicobacter pylori eradication inducing less impact on the gut microbiota. Gut Pathog. 2025;17(1):7. doi: 10.1186/s13099-025-00682-8.
Cheng J, Fan C, Li Z, Dong Z, Zhao X, Cai Y, et al. RealWorld Situation of Eradication Regimens and Risk Factors for Helicobacter pylori Treatment in China: A Retrospective Single-Center Study. Clin Exp Gastroenterol. 2024;17:191-200. doi: 10.2147/CEG.S466975.
Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol. 2020;26(32):4846-56. doi: 10.3748/wjg.v26.i32.4846.
Ouyang M, Zou S, Cheng Q, Shi X, Zhao Y, Sun M. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or without Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis. Pharmaceuticals. 2024;17(6):698. doi: 10.3390/ph17060698.
Paz S, Florez-Bracho L, Lasa J, Zubiaurre I. Infección por Helicobacter pylori: Frecuencia del fracaso del tratamiento de primera línea. Medicina (B Aires). 2020;80(2):111-16.
Peña-Galo E, Gotor J, Harb Y, Alonso M, Alcedo J. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. Gastroenterol Hepatol Bed Bench. 2021;14(1):53-8. doi: 10.22037/ghfbb.v14i1.1788.
Tang Y, Tang G, Pan L, Zhu H, Zhou S, Wei Z. Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China. Sci Rep. 2020;10(1):15403. doi: 10.1038/s41598-020-72400-0.
Yokota N, Ae R, Amenomori M, Kitagawa K, Nakamura T, Yokota T, et al. Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care. J Gen Fam Med. 2019;20(4):139-45. doi: 10.1002/jgf2.245.
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, et al. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106(1):81-7. doi: 10.1016/j.diabres.2014.07.009.
Ford A, Yuan, Y, Park J, Forman D, Moayyedi P. Eradication Therapy to Prevent Gastric Cancer in Helicobacter pylori– Positive Individuals: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Gastroenterology. 2025;169(2):261-276. doi: 10.1053/j. gastro.2024.12.033.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Renatto Ruiz-Cortez, Mirko Damas-Valera, Grecia Galvez-Nino, Frine Samalvides-Cuba, Carlos Barreda-Costa, Jorge Espinoza-Ríos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 